132740-52-4

Usage

Uses

Used in Pharmaceutical Industry:
4-Piperidinemethanamine,1-(1-methylethyl)-(9CI) is used as an intermediate in the synthesis of pharmaceuticals for its unique chemical properties and reactivity. It can be used to develop new drugs with specific therapeutic effects.
Used in Chemical Industry:
4-Piperidinemethanamine,1-(1-methylethyl)-(9CI) is used as a building block in the synthesis of other organic chemical compounds. Its unique structure allows for the creation of new molecules with potential applications in various fields.

InChI:InChI=1/C9H20N2/c1-8(2)11-5-3-9(7-10)4-6-11/h8-9H,3-7,10H2,1-2H3

Upstream product

• 534595-60-3 (1-Isopropyl-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester 
• 280115-83-5 1-isopropylpiperidine-4-carboxamide 
• 135632-53-0 tert-butyl N-(4-piperidinylmethyl)carbamate 

Downstream Products

• 869002-72-2 (4-chlorophenyl)-{2-[(1-isopropylpiperidin-4-ylmethyl)amino]-3-methyl-3H-imidazol-4-yl}methanone 
• 1025065-75-1 N-((1-isopropylpiperidin-4-yl)methyl)-3-(3(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 1331742-44-9 C₂₁H₂₅F₃N₆O 

Relevant academic research and scientific papers

Pyrazole-derivatives as factor Xa inhibitors

The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA

This application relates to heteroaromatic amides (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Antithrombotic amides

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermidates thereof.

Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists

This invention provides compounds of Formula I having the structure wherein A, B, Z, R and R1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Novel substituted 4-aminomethylpiperidines as potent and selective human β3-agonists. Part 1: Aryloxypropanolaminomethylpiperidines

The synthesis and SAR of a series of human β3 adrenoreceptor agonists based on a template derived from a common pharmacophore coupled with 4-aminomethylpiperidine is described. Potent and selective agents were identified such as 26 that was in vitro active in CHO cells expressing human β3-AR (EC50=49 nM, IA=1.1), and in vivo active in a transgenic mouse model.